The purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (NSCLC), who are being treated with an immune checkpoint inhibitor.
≥ 18 years of age at the time of consent.
Must be able to speak, read, and understand English.
have advanced/metastatic disease who are currently receiving immunotherapy monotherapy, or
have locally advanced disease who are currently receiving immunotherapy monotherapy after completing thoracic radiation therapy, or
Participants who have received a dose of chemotherapy (including maintenance pemetrexed) within the past 3 months
Participants who have received radiation therapy within the past 3 months. Note: a short course of palliative radiation therapy within up to 20 Gy and up to 5 fractions is permissible.
Diagnosis of dementia.
Anemia Hgb <10 g/dL.
Wake Forest University Health Sciences
Lead sponsor
Atrium Health Levine Cancer Institute
Collaborator